bluuebunny/crossref_metadata_2025_split huggingface dataset:
Differential expression of nucleolin in colon adenoma and adenocarcinoma
Authors: Meng Guozhao , Yi Junlei , Xie Ming 
Published: June 2023

Abstract

Objective
The aim of the study was to investigate the discrepancy in nucleolin expression between colon adenoma and colon adenocarcinoma, explore the role of nucleolin expression in the carcinogenesis of colon adenocarcinoma, and determine the correlation of the nucleolin expression level with histological grade in colon adenocarcinoma.

Methods
In total, 80 cases of colon adenocarcinoma with cancer-adjacent colon mucosa and 60 cases of colon adenomas were examined by immunohistochemistry using an antibody against nucleolin. Nucleolin expression levels in these groups were compared. The correlation between the nucleolin expression level and grade of colon adenocarcinoma was analyzed.

Results
Nucleolin expression is located in the nuclei of colon adenocarcinoma, colon adenoma, and cancer-adjacent colon mucosa tissues with different intensities. A semiquantitative evaluation using the Allred scoring system showed that the nucleolin immunostaining score in colon adenocarcinoma (7.8 ± 0.1) was significantly higher than those in colon adenoma (6.3 ± 0.2) and cancer-adjacent colon mucosa (5.4 ± 0.1; P < 0.01). The nucleolin immunostaining score in colon adenoma was significantly higher than that in cancer-adjacent colon mucosa (P < 0.01). Nucleolin expression levels in well-differentiated and moderately differentiated adenocarcinoma (6.8 ± 0.2) were significantly lower than those in poorly differentiated adenocarcinoma (8.0 ± 0.1; P < 0.01).

Conclusion
Increased nucleolin expression may play an important role in the process of malignant transformation of colon adenocarcinoma and predicts a poor prognosis.
Expression and significance of carcinoembryonic antigen, cancer antigen 153, and cyclooxygenase-2 in breast cancer ⁎
Authors: Chen Ying , Wang Jing 
Published: June 2023

AbstractObjectiveThis study aimed to evaluate serum and nipple discharge levels of carcinoembryonic antigen (CEA) and cancer antigen 153 (CA153) and tissue cyclooxygenase-2 (COX-2) expression in breast cancer cases and associations of these proteins with breast cancer metastasis.MethodsThe immunohistochemicalUltra SensitiveTMS-Pmethod was used to detect COX-2 expression in 77 cases of invasive breast carcinoma. Of these cases, 52 exhibited CEA and CA153 in both serum and nipple discharge (electrochemiluminescence method), and associations of these biomarkers with breast cancer prognosis were studied. Sixty cases of benign breast lesion were selected as a control group. Overall survival of breast carcinoma patients was evaluated. COX-2 expression was evaluated relative to clinicopathological features and CEA and CA153 levels, and its role in invasiveness was investigated.ResultsAmong cases of invasive breast cancer, 72.7% (56/77) were COX-2 immunopositive, compared to 16.7% of benign lesions (χ2= 66.745,P= 0.000) percentage of positive cells. COX-2 overexpression in breast cancer correlated positively with histological grade (II vs III; χ2= 4.064,P= 0.043), lymph node metastasis (χ2= 9.135,P= 0.003), and distant metastasis (χ2= 8.021,P= 0.003). However, COX-2 expression did not correlate with age (≤ 50 vs 50 years) or tumor size (≤ 5 vs > 5 cm) (χ2= 0.081,P= 0.776 and χ2= 3.702,P= 0.054, respectively). Among breast cancer patients, COX-2 overexpression in tumors also correlated with shorter overall survival (P< 0.05). In brief, increased COX-2 expression correlates with worse prognosis and shorter overall survival. Malignant lesions were associated with significantly higher serum and nipple discharge levels of biomarkers, relative to benign lesions (P< 0.05). These biomarkers were present at significantly higher levels in nipple discharge than in serum (P< 0.05). Furthermore, significantly higher nipple discharge levels of CEA and CA153 were observed in COX-2-positive breast carcinoma patients, compared to COX-2-negative patients (P<0.05). Shorter overall survival in cancer patients group related to COX-2 overexpression in tumors (P< 0.05).ConclusionThe study suggests that COX-2 overexpression correlates with poor clinicopathological parameters in breast cancers and might be an important biological marker of invasion and metastasis. The findings of the present study suggest that combined detection of COX-2 tissue expression and CEA and CA153 in serum and nipple discharge could facilitate clinical monitoring and diagnosis of metastasis in patients with breast cancer.
The efficacy of Kanglaite injection during treatment with tyrosine kinase inhibitor in elderly patients with non-small cell lung cancer ⁎
Authors: Zhou Wei , Han Tao , Liu Zhaozhe , Yang Xiaodan , Liu Yu , Wang Wei , Yang Benqiang , Xie Xiaodong 
Published: June 2023

Abstract

Objective
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients. The Kanglaite injection (KLT) is a novel broad-spectrum anti-cancer injection produced from traditional Chinese medicinal herbs (coix seed). After its approval in 1995, KLT has become the most popular anti-cancer drug in China. As of this writing, no standard treatment guideline is available for elder patients with NSCLC, and the role of traditional Chinese medicinal herbs, including KLT, combined with TKI treatment remains unknown. This retrospective study evaluated the efficacy and safety of KLT in elderly NSCLC patients during TKI treatment.

Methods
Thirty elderly patients aged 71-79 years with histopathologically confirmed NSCLC attending the General Hospital of the Shenyang Military Region were enrolled in the study and received EGFR-TKI treatment. All participants received 200 mL KLT injections at the same time on days 1-21. Erlotinib (150 mg) or gefitinib (250 mg) was administered daily from days 1 to 21, and the cycle was repeated every 21 days. The endpoint of the primary study was the disease control rate.

Results
Thirty elderly patients were enrolled in this study. The objective response rate was 21.3% [95% confidence interval (CI): 8.6% to 35.2%], whereas the disease control rate was 80.4% (95% CI: 71.8% to 97.0%). The grade 3 or 4 adverse effects included leucopenia (13.7%), neutropenia (13.4%), anemia (2.9%), and nausea or vomiting (2.7%).

Conclusion
The administration of KLT combined with erlotinib or gefitinib showed high efficacy in elderly NSCLC patients. The adverse effects of the drug combination were well tolerated by the patients. KLT combined with TKI treatment might provide a satisfactory therapeutic strategy for elderly NSCLC patients.
Use of 1.32-μm and 1.06-μm wavelength lasers for vascular cutting in a porcine model of liver and stomach bleeding ⁎
Authors: Han Lu , Gao Wenyuan , Shen Yangyang , Pang Kai , Jiang Zhanjun , Gao Yonghui , Xu Peng , Li Sheng 
Published: June 2023

Abstract

Objective
The aim of this study was to analyze and evaluate 1.32-μm and 1.06-μm neodymium-doped yttrium aluminum garnet (Nd:YAG) lasers for use in liver and gastroepiploic vessel vaporization and coagulation.

Methods
The effects of 1.32-μm and 1.06-μm Nd:YAG lasers were compared for gastroepiploic vessel hemostasis in porcine liver.

Results
The results were observed and measured under the same parameters and dose conditions. The 1.32-μm laser showed greater vaporization width and depth than the 1.06-μm laser. Both lasers controlled active bleeding. The coagulation band with the 1.32-μm laser was thinner than with the 1.06-μm laser, at nearly 3 mm. After cutting of 1- and 2-mm porcine vessels, no grossly visible bleeding was apparent. Intravascular thrombus was visible under the microscope. The length of vessel thrombosis in the experimental group was 2 mm and the diameter was 2 mm; the control group exhibited thrombi as 2.3-4.9 mm in length. Thrombosis completely blocked the blood vessels.

Conclusion
The 1.32-μm laser had greater vaporization capability than the 1.06-μm laser and achieved hemostasis requirements for vessels less than 2 mm in diameter.
Low-dose fractionated radiation reverses cisplatin resistance in ovarian cancer cells via PI3K/AKT/GSK-3β signaling
Authors: Jia Xiangmin , Ming Jie , Nie Xiaofei , Liang Donghai , Jiang Tao , Liu Shihai , Yu Hongsheng 
Published: June 2023

AbstractObjectiveTo investigate whether low-dose fractionated radiation (LDFRT) could enhance cisplatin sensitivity in drug-resistant human ovarian cancer cells SKOV3/DDP, and to further explore the underlying mechanism.MethodsSKOV3/DDP ovarian cancer cells were divided into three groups as follows: control, LDFRT, and conventional-dose radiation groups. Cells from all three groups were treated with different concentrations of cisplatin (0, 1.25, 2.5, 5, 10, and 20 μg/mL) for 48 h. The proliferation inhibition rate was investigated using the cell counting kit 8 (CCK8). The rate of apoptosis was determined by flow cytometry (FCM). Protein levels of AKT, P-AKT, GSK-3β, P-GSK-3β, P21, cyclin D1, and P27 were examined by Western blotting.ResultsAs expected, LDFRT significantly reduced the half-maximal inhibitory concentration (IC50) of cisplatin and promoted apoptosis in SKOV3/DDP cells. Moreover, in the LDFRT group, protein levels of P-AKT, P-GSK-3β, and cyclin D1 were markedly decreased, those of P21 and P27 were greatly increased, and total AKT and GSK-3β levels showed no significant difference compared to those in both the control and conventional-dose radiation groups.ConclusionLDFRT sensitizes resistant SKOV3/DDP ovarian cancer cells to cisplatin through inactivation of PI3K/AKT/GSK-3β signaling.
Whole process control and precision therapy in lung cancer
Authors: Liu Zhaozhe , Xie Xiaodong 
Published: June 2023

Xiaodong Xie
Professor and Chairman, Cancer Center of People’s Liberation Army, General Hospital of Shenyang Military Region, China. In 1980, he entered the Fourth Military Medical University of PLA in Xi’an, and he acquired a Master’s degree in Urology in 1996. From 2000 to 2001, he studied as a research fellow in the Department of Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences. At present, he is a doctoral supervisor at the Liaoning University of Chinese Medicine and the Fourth Military Medical University. He is a member of the council of the Chinese Anti-Cancer Association (CACA), a member of the standing committee of the Professional Committee of Cancer Rehabilitation and Palliative Care (CRPC) of the CACA, a member of the standing committee of the Professional Committee of Tumor Markers of the CACA, an Executive Member of the Chinese Society of Clinical Oncology (CSCO), a Member of the Standing Committee of the Chinese Medical Doctor Association (CMDA), and Vice Chairman of the Cancer Professional Committee of the People’s Liberation Army. In 2012, he received the Second Award of Scientific and Technological Advancement in Liaoning Province, and received the Outstanding Paper Award at the annual meeting of the CACA-CRPC.
Acupuncture relieves chemotherapy-induced refractory hiccup: A report of two cases
Authors: Li Xingyang , Wang Xianfeng , Tang Yongquan , Ren Tao 
Published: June 2023

Abstract
The aim of the study was to present two cases that illustrate the beneficial effects of acupuncture on chemotherapy-induced refractory hiccup in cancer patients. This report described two patients with diffuse large B cell lymphoma (DLBCL) and right upper pulmonary lobe moderate-differentiation adenocarcinoma (pT1N0M0) who experienced chemotherapy-induced refractory hiccup. Alternative treatment was administered to relieve the symptoms of refractory hiccup. The patients were treated with acupuncture 30 min prior to chemotherapy. The selected acupoints included Zusanli (ST36), Taichong (LR3), Zhongwan (CV12), Jiuwei (RN15), and Neiguan (PC6). The symptoms related to chemotherapy-induced refractory hiccup were completely relieved after treatment with 2 to 3 cycles of acupuncture. Based on our experience, we conclude that these two cancer patients benefited from acupuncture treatment, suggesting that acupuncture not only plays a role in pain control, but is also effective in relieving chemotherapy-induced refractory hiccup in cancer patients. The beneficial outcomes need large-scale studies to examine the effectiveness of acupuncture treatment for relieving chemotherapy-induced refractory hiccup in cancer patients.
Primary urachal adenocarcinoma: a rare case report
Authors: Liu Kaihua , Wang Hongqiang , Yu Lei , Wang Peitao , Liu Zhijun , Sun Lijiang , Yu Hongsheng , Li Shenqian 
Published: June 2023

Abstract
Primary urachal carcinoma is a very rare cancer with a poor prognosis. It generally presents as a high-grade, high-stage tumor, and in most cases the patient has developed regional or distant metastasis at the time of presentation. Here, we report a very interesting case of primary urachal adenocarcinoma with signet ring cell carcinoma in a 58-year-old male who presented with a lower abdominal mass and discomfort. In this case, urachal carcinoma was successfully treated with surgery using an extended partial bladder cystectomy approach with excision of the urachal mass and umbilicus. The patient also underwent systematic chemotherapy with 5-fluorourical and cisplatin. During the 12-month follow-up period, the patient did not experience recurrence or metastasis. Overall, we found that an organ preserving extended partial cystectomy along with chemotherapy was an optimal treatment method that helped improve the patient's quality of the life with no recurrence of cancer so far.
Effects of Nordy on the proliferation, differentiation, and apoptosis of HPV16 subgene-immortalized human endocervical cells*
Authors: Chen Wei , Zhao Yong , Bian Xiuwu 
Published: June 2023

Abstract

Objective
The aim of this study was to investigate the effects of Nordy on the proliferation, differentiation, and apoptosis of HPV16 subgene-immortalized human endocervical cells (H8 cells).

Methods
After treatment with Nordy, H8 cell proliferation was evaluated using the MTT assay. The effects of Nordy on the cell cycle and apoptosis of H8 cells were analyzed by flow cytometry (FCM) and the Annexin V-FITC method. H8 cell MCM5 expression was detected by immunocytochemistry. Morphological changes were observed by light and electron microscopy. Telomerase activity was evaluated by TRAP-ELISA.

Results
We found that 10 µmol/L-100 µmol/L Nordy significantly inhibited H8 cell proliferation. After treatment with Nordy, H8 cells were blocked in the G0/G1 phase, and the rate of cell apoptosis increased significantly. Cells differentiated toward innocuousness, and MCM5 expression and telomerase activity notably decreased.

Conclusion
Nordy was observed to inhibit proliferation and promote apoptosis in H8 cells. Nordy also induced H8 cell differentiation; this effect may have been achieved by blocking the cell cycle and decreasing telomerase activity.
Postoperative sequential chemotherapy and radiotherapy for locally advanced gastric cancer
Authors: Fu Qiang , Yu Shiying , Hu Guoqing , Chen Yuan , Hu Junbo , Zhang Lihong , Qiu Hong , Yuan Xianglin 
Published: June 2023

AbstractObjectiveThe aim of the study was to evaluate the role of postoperative sequential chemotherapy and radiotherapy in patients with locally advanced gastric cancer.MethodsFrom January 2003 to December 2010, 146 gastric cancer patients at our institution (Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) received postoperative sequential chemotherapy and radiotherapy after radical surgery. Radiotherapy was administered as a dose of 4500 cGy in 25 fractions. For patients with positive margins, the dose was raised to 5040 cGy in 28 fractions. Three cycles of mFOLFOX or PF (cisplatin, 5-fluorouracil) chemotherapy regimen were applied before and after radiotherapy. Three- and 5-year survival rates were analyzed; any adverse effects with respect to hematology, hepatic and renal function, or the gastrointestinal tract that occurred during the treatment were evaluated.ResultsThis cohort consisted of non-metastatic patients: 104 men and 42 women with a median age of 51.0 years. The full course of sequential chemotherapy and radiotherapy (4500-5040 cGy) was completed by 129 patients (88.4%). Seventeen regional relapses (9.8%) and 46 distant relapses (23.8%) were recorded. Fifty patients (34.2%) died during follow-up. The 3- and 5-year overall survival rates (OS) were 60% and 54%, and disease-free survival rates (DFS) were 53% and 47%, respectively. There were no significant differences in survival rate with respect to age, sex, histopathology, N stage, site of the tumor, or margin status. Multivariate analysis showed that only the depth of tumor invasion (T stage) was an independent prognostic factor for OS (P= 0.009) and DFS (P= 0.006). The rates of grades 3 and 4 neutropenia and vomiting were 9.6% and 3.4%, respectively, during the treatment.ConclusionPostoperative sequential chemotherapy with an mFOLFOX or PF regimen and radiotherapy were found to be an effective means of treating advanced gastric cancer patients with T3-T4 disease. The adverse effects of this treatment were tolerable.
Protective effects of probucol in rats with postoperative acute renal failure*
Authors: Yang Cheng , Peng Jun , Ren Xingfeng 
Published: June 2023

Abstract

Objective
We investigated the protective effect of probucol in rats with acute renal failure caused by various ischemia-reperfusion injuries (IRIs) after surgery.

Methods
Forty male Sprague-Dawley rats were randomly divided into a sham operation group (S group), ischemia reperfusion group (IR group), probucol low-dose treatment group (probucol + IR group 1, P+ IR 1 group; probucol 250 mg/kg intragastric administration daily), and probucol high-dose treatment group (P + IR 2 group; probucol 500 mg/kg intragastric administration daily). Rats in the S and IR groups were intragastrically administered with warm water every day. After 1 week, the kidney IRI rat models were prepared, after which the rats were fed for another week, and blood, urine, and the kidney tissue specimens were retained. A series of biochemical indices, superoxide dismutase (SOD), and malondialdehyde in the serum and kidney tissues were detected, and pathological changes in renal tissue were observed.

Results
Twenty-four-hour urinary protein excretion, urinary NAGase, CysC, blood urea nitrogen (BUN), and creatinine were significantly lower in the P + IR 1 and P + IR 2 groups than in the IR group (P < 0.05). Superoxide dismutase in the serum and renal tissue increased significantly, malondialdehyde decreased significantly (P < 0.05), renal pathological injury was alleviated, and the kidney index improved significantly (P < 0.05).

Conclusion
Probucol can relieve various types of acute renal failure in postoperative rats.
Outcomes of palliative local treatment in metastatic colorectal cancer patients receiving chemotherapy plus bevacizumab
Authors: Zhao Ben , Wang Lu , Yu Qianqian , Hu Guangyuan , Qiu Hong , Zhang Mingsheng , Sun Li , Peng Ping , Yuan Xianglin 
Published: June 2023

Abstract

Objective
The aim of this study was to assess the value of palliative local treatment of incurable metastatic lesions in colorectal cancer (CRC) patients receiving chemotherapy plus bevacizumab.

Methods
Data of 105 patients with histologically confirmed synchronous or metachronous metastatic CRC who received bevacizumab treatment from January 1, 2011 to January 31, 2017 were retrospectively reviewed. Sixteen (15%) patients who were treated with bevacizumab for less than 4 cycles were excluded, and finally, 89 (85%) patients were enrolled. Among them, 33 (37%) patients who received palliative local treatment were categorized into the palliative local treatment group, and the remaining 56 (63%) patients were categorized into the chemotherapy plus bevacizumab group. The primary endpoint was overall survival (OS), which was calculated using Kaplan-Meier survival analyses. Factors possibly influencing survival were evaluated by univariate and multivariate analyses. Adverse events (AEs) were graded according to Common Terminology Criteria for Adverse Events, version 4.0. Grades 1-2 and 3-4 AEs of the two groups were compared and analyzed using the Fisher's exact test and χ2 analysis.

Results
The median follow-up period was 20.4 months, ranging from 1 to 60 months. The median OS in the palliative local treatment group was 36.3 months (95% CI, 33.5-39.2), and that in the chemotherapy plus bevacizumab group was 20.5 months (95% CI, 17.6-23.4). Both the univariate (HR 0.13, 95% CI, 0.05-0.30, P < 0.001) and multivariate (HR 0.16, 95% CI, 0.07-0.39, P < 0.001) analyses showed that the addition of palliative local treatment could prolong survival compared with chemotherapy plus bevacizumab alone. There were no significant differences in the rates of common chemotherapy- or bevacizumab-related AEs between the two groups.

Conclusion
These findings suggest palliative local treatment is an effective and safe method for treating patients with incurable metastatic CRC receiving chemotherapy plus bevacizumab.
N-myc downstream-regulated gene 2 promotes proliferation of HO-8910 ovarian cancer cells
Authors: Kang Fenhong , Luo Yaping , Wang Yanlong 
Published: June 2023

Abstract

Objective
To investigate N-myc downstream-regulated gene 2 (NDRG2) expression in ovarian cancer cells and its potential usefulness as a diagnostic marker and/or target for therapeutic intervention.

Methods
Human NDRG2L/S gene was obtained by revers-transcription polymerase chain reaction (RT-PCR). Sequence analysis confirmed the identity of NDRG2L/S gene, which was then inserted into a eukaryotic vector pLNCX2, which was in turn transfected into NDRG2 gene-negative HO-8910 cells. Flow cytometry (FCM) and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay were conducted to determine the proliferation rate of HO-8910 cells. Cisplatin resistance of HO-8910 cells transfected with pLNCX2-NDRG2L/S was evaluated by FCM. Tumors were generated in female nude mice by subcutaneous injection of HO-8910 cells.

Results

NDRG2 gene was isolated and its expression vector was successfully constructed. NDRG2 expression positively correlated with the proliferation of HO-8910 cells. NDRG2L/S promoted tumorigenicity in HO-8910 cells.

Conclusion
The present study identified a novel function of NDRG2L/S gene and demonstrated its involvement in the promotion of ovarian cancer cell proliferation and enhancement of cisplatin resistance in HO-8910 cells. Future studies are warranted to determine the relationship between NDRG2 upregulation and ovarian cancer progression.